Table S1. P values of each variable for each stratum between BP+VD treatment and the other treatment groups after propensity score adjustment.

|  |  |
| --- | --- |
|  | Stratum |
| **Variables** | 1 | 2 | 3 | 4 | 5 |
| Female | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Age (years) | 0.54 | 0.51 | 1.00 | 1.00 | 0.99 |
| Post menopause | 1.00 | 0.62 | 1.00 | 0.50 | 0.43 |
| Duration of disease (year) | 0.94 | 0.76 | 1.00 | 0.24 | 0.06 |
| SLEDAI-2K | 0.94 | 0.95 | 0.24 | 0.95 | 0.83 |
| History of LN | 1.00 | 1.00 | 0.60 | 0.18 | 1.00 |
| Hypertension | 0.59 | 1.00 | 0.61 | 1.00 | 1.00 |
| CKD | 0.53 | 0.48 | 1.00 | 0.37 | 0.55 |
| eGFR (mL/min) | 0.54 | 0.76 | 0.50 | 0.86 | 0.69 |
| Serum creatinine (mg/dL) | 0.41 | 0.76 | 0.66 | 0.68 | 0.83 |
| History of CVD | 1.00 | 1.00 | 0.06 | 0.57 | 1.00 |
| T-score of BMD\* | 0.94 | 1.00 | 0.88 | 0.75 | 0.20 |
| Low BMD | 0.53 | 1.00 | 0.30 | 0.37 | 0.55 |
| Mean IMT (mm) | 0.69 | 0.76 | 0.66 | 0.99 | 0.99 |
| Cumulative dose of GC (g\*\*) | 0.98 | 0.58 | 0.79 | 0.89 | 0.07 |
| Duration of GC use (month) | 0.94 | 0.64 | 0.99 | 0.49 | 0.09 |
| Current dose of GC (mg\*\*/day) | 0.61 | 0.44 | 0.94 | 0.09 | 0.99 |
| Concomitant use of IS | 1.00 | 1.00 | 1.00 | 0.89 | 0.49 |
| Antihypertensive agent | 0.59 | 1.00 | 0.32 | 0.79 | 1.00 |
| Statin | 1.00 | 1.00 | 1.00 | 1.00 | 0.55 |

Binary variables were compared using either χ2 test or Fischer’s exact test, continuous variables compared using Kolmogorov-Smirnov test of strata balance after propensity score adjustment.

\*Smaller value of T-score was taken either lumber or femoral neck.

\*\*Prednisolone equivalents

BP: bisphosphonate, VD: vitamin D agent, BMI: body mass index, SLE: systemic lupus erythematosus, SLEDAI-2K: SLE disease activity index 2000, LN: lupus nephritis, CKD: chronic kidney disease, eGFR: estimated glomerular filtration rate, CVD: cardiovascular disease, BMD: bone mineral density, F.N: femoral neck, IMT: intima-media thickness, GC: glucocorticoid, IS: immunosuppressant